News
The c-Met protein thought to be both a driver of cancer itself, as well as a resistance mechanism that tumours can develop to protect them from some widely-used NSCLC therapies, including EGFR ...
The c-Met protein is thought to be both a driver of cancer itself and a resistance mechanism that tumours can develop to protect them from some widely-used NSCLC therapies, including EGFR inhibitors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback